← Back to Search

Antibacterial Agent

Treatment for COVID-19 (DAP-CORONA Trial)

Phase 3
Waitlist Available
Led By Jean Bourbeau, MD,MSc,FRCPC
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days post randomization
Awards & highlights

DAP-CORONA Trial Summary

This study is evaluating whether dapsone can help treat COVID-19.

Eligible Conditions
  • COVID-19
  • Coronavirus

DAP-CORONA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days post randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days post randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Composite outcome: All cause pre-hospitalization death or all-cause hospitalization
Secondary outcome measures
All-cause ICU admission
All-cause death
Drug safety (Adverse Event (AE) and Serious Adverse Event (SAE)) for short term therapy in COVID-19 patients
+5 more

DAP-CORONA Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: TreatmentActive Control1 Intervention
Participants will receive standard of care and Dapsone per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced. Dosage form: Dapsone oral tablet
Group II: ControlPlacebo Group1 Intervention
Participants will receive standard of care and placebo per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced. Dosage form: Placebo oral tablet

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
441 Previous Clinical Trials
156,074 Total Patients Enrolled
13 Trials studying COVID-19
3,111 Patients Enrolled for COVID-19
Pulmonem Inc.UNKNOWN
Jean Bourbeau, MD,MSc,FRCPCPrincipal InvestigatorRI-MUHC

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Pennsylvania
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19
Jean Bourbeau 2021. "Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04935476.
All > Coronavirus
~900 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top